Anisina (ATM-3507)

News alerts, weekly reports and conference planners

Company:

Kazia

Drug class:

Tropomyosin 3 inhibitor

‹

›

3ms

The tropomyosin 3.1/3.2 inhibitor ATM-3507 alters B-cell actin dynamics and impairs the growth and motility of diffuse large B-cell lymphoma cell lines. (PubMed, Front Immunol)

Furthermore, ATM-3507 markedly reduced CXCL12-stimulated chemotaxis and integrin-dependent motility of DLBCL cell lines on fibronectin. Tpm3.1/3.2 orchestrates key actin-driven processes in B cells, and drugs that target Tpm3.1/3.2 may be useful adjuncts for treating DLBCL.

3 months ago

Preclinical • Journal

TPM3 (Tropomyosin 3) • CXCL12 (C-X-C Motif Chemokine Ligand 12)

Anisina (ATM-3507)

almost5years

Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. (PubMed, Br J Cancer)

Combined targeting of Tpm3.1/actin and microtubules is a promising treatment strategy for ovarian cancer that should be further tested in clinical settings.

almost 5 years ago

Journal

CCND1 (Cyclin D1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)

paclitaxel • vinorelbine tartrate • Anisina (ATM-3507)